Researchers from the University of Michigan (UM), the Medical College of Wisconsin at Milwaukee (MCW) and the University of Chicago GLRCE Small Animal Research and Immunology Cores (UC), collaborate on a developmental project funded by the Great Lakes Regional Center of Excellence for Bio-defense and Emerging Infectious Diseases Research (GLRCE). They have formed a collaboration for development of a trivalent vaccine against three NIAID Category A agents for which the NIAID seeks high priority bio-defense products: inhalation antrax, botulism and plague. This project uses nanoemulsion-based rPA vaccines against anthrax and other nanoemulsion-adjuvanted experimental vaccines. Work on this “trivalent” vaccine could protect individuals in an emergent situation against three Category A high priority bio-defense agents.
|
